Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study (updated)

Sage Therapeutics

17/04/2024 12:05

(Adds shares, background and trial details throughout)
       April 17 (Reuters) - Sage Therapeutics  SAGE.O  said on
Wednesday it will stop development of its experimental drug to
treat Parkinson's disease after it failed a mid-stage study,
sending the company's shares down 4% before the bell.
    Parkinson's disease, a progressive movement disorder of the
nervous system, affects about 1 million people in the United
States.
    Sage Therapeutics' drug, dalzanemdor, did not show
statistically significant differences in patients with mild
cognitive impairment due to Parkinson's compared to a placebo,
the company said.

 (Reporting by Mariam Sunny in Bengaluru; Editing by Shounak
Dasgupta)
 ((Mariam.ESunny@thomsonreuters.com))